by Vineti | March 26, 2021
As the creator of the leading digital platform for orchestrating cell and gene therapies, Vineti knows the operational hurdles faced by advanced therapy clinical trial teams. Here is an overview of some of the key challenges in cell and gene therapy…
Biopharmaceutical and technology leaders form collaboration to promote standards and a modern patient ID for advanced therapies
by Amy DuRoss | March 25, 2021
SAN FRANCISCO, March 24, 2021 (GLOBE NEWSWIRE) — A broad coalition of biopharmaceutical and technology leaders today announced a new strategic collaboration to promote new and updated standards for advanced therapies. The new collaboration, which…
by Vineti | February 3, 2021
2020 was a volatile year for cell and gene therapy R&D, but important progress persevered. Here are some of the numbers that mattered most -- and a few that point to a coming rebound.
Introducing new Vineti PTM® flexibility features: next-gen label printing and rescheduling innovations deliver critical workflow options that advanced therapies require
by Amy DuRoss | January 11, 2021
SAN FRANCISCO, January 11, 2020 (Globe Newswire) — Vineti, the leading provider of a digital platform of record for personalized therapeutics, today announced a new suite of flexibility features for its Personalized Therapy Management® (PTM)…
by Phil Calvin | November 30, 2020
Phil Calvin, Vineti’s Chief Technology Officer, is a long-time leader in enterprise software, with more than 25 years of entrepreneurial and executive experience, including nearly a decade at Salesforce.